This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mair, J. Articles by Bode-Böger, S. M. Search for Related Content PubMed PubMed Citation Articles by Mair, J. Articles by Bode-Böger, S. M.

(Circulation. 1998;97:1209-1210.)
© 1998 American Heart Association, Inc.

Correspondence

Is Measurement of Cyclic Guanosine Monophosphate in Plasma or Urine Suitable for Assessing In Vivo Nitric Oxide Production?

Johannes Mair, MD; ; Bernd Puschendorf, MD

Department of Medical Chemistry and Biochemistry, University of Innsbruck, Innsbruck, Austria

To the Editor:

In their recently published article on nitric oxide (NO) synthesis in patients with peripheral arterial occlusive disease Böger et al¹ based their conclusions among others on urinary excretion of cyclic guanosine monophosphate (cGMP). The increasing use of urinary and plasma cGMP as a marker of NO production prompts us to critically comment on the basis of doing this. NO stimulates soluble guanylate cyclase and elevates intracellular cGMP.² The other isoenzyme of guanylate cyclase, particulate guanylate cyclase, is stimulated by natriuretic peptides, which also leads to an increase in intracellular cGMP.³ The induction of cGMP either by natriuretic peptides, NO, or nitrates in target tissues may cause an egression of cGMP into the supernatant.^{4 5} We observed a release of cGMP into the medium after stimulation of human internal mammary artery grafts with either atrial natriuretic peptide (ANP) or SIN-1 (unpublished results). However, much higher concentrations of SIN-1 were necessary to achieve comparably high cGMP concentrations in the medium.

In humans, ANP injections cause a rapid and pronounced increase in plasma and urinary cGMP,^{6 7} whereas nitroglycerol infusions or molsidomine injections lead to a nonsignificant increase or no increase in peripheral venous plasma cGMP concentrations.^{6 8} cGMP is only partly eliminated from plasma by glomerular filtration, and most of plasma cGMP is eliminated by extrarenal clearance. Urinary cGMP is primarily of renal cellular origin and correlated with the natriuresis induced by ANP.⁸ Therefore urinary cGMP has been proposed as a biologic marker for the renal activities of natriuretic peptides in vivo.⁸ . . . [Full Text of this Article]

Rainer H. Böger, MD; ; Stefanie M. Bode-Böger, MD

Institute of Clinical Pharmacology, Medical School, Hannover, Germany

This article has been cited by other articles:

				J. Magne, J. F. Huneau, D. Tsikas, S. Delemasure, L. Rochette, D. Tome, and F. Mariotti Rapeseed Protein in a High-Fat Mixed Meal Alleviates Postprandial Systemic and Vascular Oxidative Stress and Prevents Vascular Endothelial Dysfunction in Healthy Rats J. Nutr., September 1, 2009; 139(9): 1660 - 1666. [Abstract] [Full Text] [PDF]

				R. Maas, E. Schwedhelm, L. Kahl, H. Li, R. Benndorf, N. Luneburg, U. Forstermann, and R. H. Boger Simultaneous Assessment of Endothelial Function, Nitric Oxide Synthase Activity, Nitric Oxide-Mediated Signaling, and Oxidative Stress in Individuals with and without Hypercholesterolemia Clin. Chem., February 1, 2008; 54(2): 292 - 300. [Abstract] [Full Text] [PDF]

				M. L. Summar, J. V. Gainer, M. Pretorius, H. Malave, S. Harris, L. D. Hall, A. Weisberg, D. E. Vaughan, B. W. Christman, and N. J. Brown Relationship Between Carbamoyl-Phosphate Synthetase Genotype and Systemic Vascular Function Hypertension, February 1, 2004; 43(2): 186 - 191. [Abstract] [Full Text] [PDF]

				M. Bogdan, M. Humbert, J. Francoual, C. Claise, P. Duroux, G. Simonneau, and A. Lindenbaum Urinary cGMP concentrations in severe primary pulmonary hypertension Thorax, December 1, 1998; 53(12): 1059 - 1062. [Abstract] [Full Text]